脂肪量和肥胖相关基因在代谢相关脂肪性肝病发生发展中的作用机制及相关靶向治疗

打开文本图片集

Abstract：Metabolicdysfunction-associatedfattyliverdisease（MAFLD）isacommonchronicliverdiseasewiththepathological featureoflipidaccumulationintheliver，nditisloselyasociatedwithlivermetabolicdisorders.Thelatestresearchhasshown thatthepathogenesisofMAFisassociatedwiththeabnoalexpresioofspecificgenes，especiallythefatmassandbsity associated（FTO）gene.Theabnormalactivityof theFTOgene mayleadtoanimbalanceinliverlipidmetabolism，whichmanifests astheincreaseinfattyacidsynthesisandthereductioninfatyacidoxidation，therebypromoting liverfatdepositionand inflammatoryresponse.ThereforeegulatingtheexpressionoractivityoftheFTOgeneisconsideredoneoftepotentialtategies forth treatmentofMAFLD.Atpresent，drugresearch targetingthfunctionoftheFOgenehasachievedpreliminaryresults，and inhibitionof theactivityoftheFTOgenecanhelptoregulateliverlipidmetabolismandallviateliverinflammatoryinjury.This articlereviewsthemechanismofactionof theFTOgeneinthedevelopmentandprogresionofMAFLD，summarizestheadvances in drugresearchontheFTO geneandrelated metabolic pathways inrecent years，andanalyzes theirapplication prospect in research and treatment.

Key Words：Alpha-Ketoglutarate-Dependent DioxygenaseFTO；Non-alcoholicFattLiver Disease；Lipid MetabolismDisorders； Genetic Therapy

Researchfunding：NationalNaturalScienceFoundationofChina（82160837）；GuangxiUniversityof Traditional Chinese MedicineQihuang EngineeringHigh-level TalentCultivation Project（2O21007）

代谢相关（非酒精性）脂肪性肝病（metabolicdysfunction-associatedfattyliverdisease，MAFLD）是一种广泛性肝脏疾病，其主要特征是肝内脂肪的异常积累，并可能进一步导致肝纤维化、肝硬化、肝细胞癌，以及增加多种代谢并发症的风险[1-2]。（剩余20148字）